Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial
Name:
35394800.pdf
Size:
2.301Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Gounder, M. M.Razak, A. A.
Somaiah, N.
Chawla, S.
Martin-Broto, J.
Grignani, G.
Schuetze, S. M.
Vincenzi, B.
Wagner, A. J.
Chmielowski, B.
Jones, R. L.
Riedel, R. F.
Stacchiotti, S.
Loggers, E. T.
Ganjoo, K. N.
Le Cesne, A.
Italiano, A.
Garcia Del Muro, X.
Burgess, M.
Piperno-Neumann, S.
Ryan, C.
Mulcahy, M. F.
Forscher, C.
Penel, N.
Okuno, S.
Elias, A.
Hartner, L.
Philip, T.
Alcindor, T.
Kasper, B.
Reichardt, P.
Lapeire, L.
Blay, J. Y.
Chevreau, C.
Valverde Morales, C. M.
Schwartz, G. K.
Chen, J. L.
Deshpande, H.
Davis, E. J.
Nicholas, G.
Gröschel, S.
Hatcher, H.
Duffaud, F.
Herráez, A. C.
Beveridge, R. D.
Badalamenti, G.
Eriksson, M.
Meyer, C.
von Mehren, M.
Van Tine, B. A.
Götze, K.
Mazzeo, F.
Yakobson, A.
Zick, A.
Lee, Alexander J
Gonzalez, A. E.
Napolitano, A.
Dickson, M. A.
Michel, D.
Meng, C.
Li, L.
Liu, J.
Ben-Shahar, O.
Van Domelen, D. R.
Walker, C. J.
Chang, H.
Landesman, Y.
Shah, J. J.
Shacham, S.
Kauffman, M. G.
Attia, S.
Affiliation
Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NYIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. Methods: SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis. (Registration: ClinicalTrials.gov identifier: NCT02606461.). Results: Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001). Conclusion: Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.Citation
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, et al. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.Journal
Journal of Clinical OncologyDOI
10.1200/jco.21.01829PubMed ID
35394800Additional Links
https://dx.doi.org/10.1200/jco.21.01829Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/jco.21.01829
Scopus Count
Collections
Related articles
- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
- Authors: Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V, ENGOT-EN5/GOG-3055/SIENDO Investigators
- Issue date: 2023 Dec 10
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
- Authors: Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
- Issue date: 2021 Aug
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
- Authors: Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA
- Issue date: 2020 Jul
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
- Authors: Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG
- Issue date: 2020 Nov
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.
- Authors: Gounder MM, Zer A, Tap WD, Salah S, Dickson MA, Gupta AA, Keohan ML, Loong HH, D'Angelo SP, Baker S, Condy M, Nyquist-Schultz K, Tanner L, Erinjeri JP, Jasmine FH, Friedlander S, Carlson R, Unger TJ, Saint-Martin JR, Rashal T, Ellis J, Kauffman M, Shacham S, Schwartz GK, Abdul Razak AR
- Issue date: 2016 Sep 10